Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amg 701 + pomalidomide
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (amg 701), Oral (pomalidomide)
01
Overview
AMG 701 + pomalidomide is an investigational combination therapy for **relapsed or refractory multiple myeloma**. **AMG 701** is a bispecific T-cell engager (BiTE) antibody construct that targets **B-cell maturation antigen (BCMA)** on multiple myeloma cells and **CD3** on T cells, redirecting T-cell cytotoxicity toward myeloma cells. **Pomalidomide** is an immunomodulatory drug (IMiD) that enhances immune cell function and has direct anti-myeloma activity. In combination, AMG 701 and pomalidomide synergistically potentiate T-cell activation, proliferation, memory formation, and cytotoxicity, leading to superior anti-myeloma activity compared to either agent alone. This combination is being evaluated in early-phase clinical trials for enhanced efficacy in patients with advanced multiple myeloma.[1][2][4][6]
02
Targets
BCMA (B-cell maturation antigen)CRBN (Cereblon)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on amg 701 + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amg 701 + pomalidomide.